EF Hutton Acquisition Co. I restated their buy rating on shares of Innoviva (NASDAQ:INVA – Get Rating) in a research note released on Thursday, Benzinga reports. The firm currently has a $22.50 price target on the biotechnology company’s stock. A number of other analysts have also recently issued reports on the company. StockNews.com assumed coverage […]